Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Abraham, G. Articles by Josiassen, R. C. Search for Related Content PubMed Citation Articles by Abraham, G. Articles by Josiassen, R. C. Schizophrenia Spectrum Disorders Symptoms/Dimensions

Effects of Elevated Serum Prolactin on Bone Mineral Density and Bone Metabolism in Female Patients With Schizophrenia: A Prospective Study

OBJECTIVE: This study was designed to prospectively examine differential effects of sustained "high" and "low" serum prolactin levels on bone mineral density and peripheral markers of bone metabolism. METHOD: A dual-energy X-ray absorptiometer was used to measure bone mineral density. Peripheral markers of bone formation and resorption were used to measure bone metabolism in 14 Caucasian female patients with schizophrenia treated with risperidone or olanzapine monotherapy over 12 months. RESULTS: Analyses of variance failed to show an association between elevated prolactin and bone mineral loss over time. However, higher rates of bone formation and resorption were seen in those with high prolactin levels. CONCLUSIONS: The results failed to show that elevated prolactin accelerates bone mineral density loss. However, sustained hyperprolactinemia did have an impact on the rate of bone metabolism. Perhaps higher prolactin levels over longer time periods are necessary before the metabolic processes become uncoupled, leading to bone mineral density loss.

This article has been cited by other articles:

				V. O'Keane Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia J Psychopharmacol, March 1, 2008; 22(2_suppl): 70 - 75. [Abstract] [PDF]

				P. A Marken and R. W Pies Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles Ann. Pharmacother., February 1, 2006; 40(2): 276 - 285. [Abstract] [Full Text] [PDF]

				S. C. Miller, B. L. Anderson, and B. M. Bowman Weaning Initiates a Rapid and Powerful Anabolic Phase in the Rat Maternal Skeleton Biol Reprod, July 1, 2005; 73(1): 156 - 162. [Abstract] [Full Text] [PDF]

				M. V. Seeman Gender Differences in the Prescribing of Antipsychotic Drugs Am J Psychiatry, August 1, 2004; 161(8): 1324 - 1333. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us